The prognostic significance of DNMT3A mutation and CD7 expression in AML is still inconclusive, and there are currently no studies exploring the clinical significance of DNMT3A mutation combined with CD7 expression in AML patients. This evidence concerns the gene CD7 and acute myeloid leukemia.